Display Settings:

Format

Send to:

Choose Destination

    Emerg Infect Dis. 2008 Nov;14(11):1756-8.

    Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.

    Zilberberg MD, Shorr AF, Kollef MH.

    EviMed Research Group, LLC, Goshen, Massachussetts 01032, USA. marya@evimedgroup.org

    From 2000 through 2005, hospitalizations with resistant infections (methicillin-resistant Staphylococcus aureus, Clostridium difficile-associated disease, vancomycin-resistant enterococcus, Pseudomonas aeruginosa, and Candida infection) nearly doubled, from 499,702 to 947,393. Regional variations noted in the aggregate and by individual infection may help clarify modifiable risk factors driving these infections.

    PMID: 18976563 [PubMed - indexed for MEDLINE]

    PMCID: 2630735

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Vancomycin (Vancocin®)

      Vancomycin is used to treat colitis (inflammation of the intestine caused by certain bacteria) that may occur after antibiotic treatment. Vancomycin is in a class of medications called glycopeptide antibiotics. It works ...